Article
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Mar 2008
Miller Vincent A, Riely Gregory J, Zakowski Maureen F, Li Allan R, Patel Jyoti D, Heelan Robert T, Kris Mark G, Sandler Alan B, Carbone David P, Tsao Anne, Herbst Roy S, Heller Glenn, Ladanyi Marc, Pao William, Johnson David H
Abstract excerpt
PURPOSE: We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response. PATIENTS AND METHODS: Patients (n = 101) with BAC (n = 12) or adenocarcinoma, BAC subtype (n = 89), were enrolled. All patients received erlotinib 150 mg daily. Epidermal growth...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
